Updated survival analysis in patients with stage IIIB or IV non-small-cell lung cancer receiving BLP25 liposome vaccine (L-BLP25): Phase IIB randomized, multicenter, open-label trial

Journal of Cancer Research and Clinical Oncology

Volumn 137, Issue 9, 2011, Pages 1337-1342

  Butts, Charles ^a   Maksymiuk, Andrew ^b   Goss, Glenwood ^c   Soulières, Denis ^d   Marshall, Ernie ^e   Cormier, Yvon ^f   Ellis, Peter M ^g   Price, Allan ^h   Sawhney, Ravinder ⁱ   Beier, Frank ^j   Falk, Martin ^j   Murray, Nevin ^k  

^a CROSS CANCER INSTITUTE   (Canada)

^b CANCERCARE MANITOBA   (Canada)

^c UNIVERSITY OF OTTAWA   (Canada)

^d UNIVERSITÉ DE MONTRÉAL   (Canada)

^e CLATTERBRIDGE CENTRE FOR ONCOLOGY   (United Kingdom)

^f UNIVERSITÉ LAVAL   (Canada)

^g JURAVINSKI CANCER CENTRE   (Canada)

^h WESTERN GENERAL HOSPITAL   (United Kingdom)

ⁱ Fraser Valley Cancer Centre   (Canada)

^j MERCK KGAA   (Germany)

^k Vancouver Cancer Centre   (Canada)

more..

Author keywords

L BLP25; MUC1; Non small cell lung cancer; Survival; Therapeutic cancer vaccine

Indexed keywords

BLP25 LIPOSOME VACCINE; CANCER VACCINE; STIMUVAX; UNCLASSIFIED DRUG;

ADULT; ARTICLE; BEST SUPPORTIVE CARE; CANCER STAGING; CANCER SURVIVAL; CONTROLLED STUDY; DRUG EFFICACY; DRUG TOLERABILITY; FLU LIKE SYNDROME; FOLLOW UP; HUMAN; INJECTION SITE REACTION; LUNG NON SMALL CELL CANCER; MAINTENANCE THERAPY; MAJOR CLINICAL STUDY; MULTICENTER STUDY; OVERALL SURVIVAL; PATIENT CARE; PHASE 2 CLINICAL TRIAL; POPULATION RESEARCH; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SURVIVAL RATE; SURVIVAL TIME; VACCINATION;

CANCER VACCINES; CARCINOMA, NON-SMALL-CELL LUNG; FEMALE; HUMANS; IMMUNOTHERAPY; LIPOSOMES; LUNG NEOPLASMS; MALE; MEMBRANE GLYCOPROTEINS; MIDDLE AGED; NEOPLASM STAGING; SURVIVAL ANALYSIS; SURVIVAL RATE;

EID: 80054742888     PISSN: 01715216     EISSN: 14321335     Source Type: Journal    
DOI: 10.1007/s00432-011-1003-3     Document Type: Article

References (24)

1. Albain KS, Crowley JJ, Turrisi AT, Gandara DR, Farrar WB, Clark JI, Beasley KR, Livingston RB (2002) Concurrent cisplatin, etoposide, and chest radiotherapy in pathologic stage IIIB nonsmall-cell lung cancer: a Southwest Oncology Group phase II study, SWOG 9019. J Clin Oncol 20:3454-3460
2. Butts C, Murray N, Maksymiuk A, Goss G, Marshall E, Soulieres D, Cormier Y, Ellis P, Price A, Sawhney R, Davis M, Mansi J, Smith C, Vergidis D, Ellis P, MacNeil M, Palmer M (2005) Randomized phase IIB trial of BLP25 liposome vaccine in stage IIIB and IV non-small-cell lung cancer. J Clin Oncol 23:6674-6681 (Pubitemid 46190262)
3. Butts C, Murray RN, Smith CJ, Ellis PM, Jasas K, Maksymiuk A, Goss G, Ely G, Beier F, Soulières D (2010) A multicenter openlabel study to assess the safety of a new formulation of BLP25 liposome vaccine in patients with unresectable stage III nonsmall-cell lung cancer. Clin Lung Cancer 11:391-395
4. ClinicalTrials.gov (2010) Cancer vaccine study for unresectable stage III non-small cell lung cancer. Available at: http://www.clinicaltrials.gov/. Accessed Feb. 2011
5. Crino L, Weder W, van Meerbeeck J, Felip E (2010) Early stage and locally advanced (non-metastatic) non-small-cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 21(Suppl 5):v103-v115
6. D'Addario G, Fruh M, Reck M, Baumann P, Klepetko W, Felip E (2010) Metastatic non-small-cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 21(Suppl 5):v116-v119
7. Ettinger DS, Bepler G, Bueno R, Chang A, Chang JY, Chirieac LR, D'Amico TA, Demmy TL, Feigenberg SJ, Grannis FW Jr, Jahan T, Jahanzeb M, Kessinger A, Komaki R, Kris MG, Langer CJ, Le QT, Martins R, Otterson GA, Robert F, Sugarbaker DJ, Wood DE (2006) Non-small cell lung cancer clinical practice guidelines in oncology. J Natl Compr Canc Netw 4:548-582 (Pubitemid 44265463)
8. Fisher MD, D'Orazio A (2000) Phase II and III trials: comparison of four chemotherapy regimens in advanced non small-cell lung cancer (ECOG 1594). Clin Lung Cancer 2:21-22
9. Formenti SC, Demaria S (2009) Systemic effects of local radiotherapy. Lancet Oncol 10:718-726
10. Gandara DR, Chansky K, Albain KS, Leigh BR, Gaspar LE, Lara PN Jr, Burris H, Gumerlock P, Kuebler JP, Bearden JD III, Crowley J, Livingston R (2003) Consolidation docetaxel after concurrent chemoradiotherapy in stage IIIB non-small-cell lung cancer: phase II Southwest Oncology Group Study S9504. J Clin Oncol 21:2004-2010 (Pubitemid 46606390)
11. Gridelli C, Rossi A, Maione P, Ferrara ML, Castaldo V, Sacco PC (2009) Vaccines for the treatment of non-small cell lung cancer: a renewed anticancer strategy. Oncologist 14:909-920
12. Hanna N, Neubauer M, Yiannoutsos C, McGarry R, Arseneau J, Ansari R, Reynolds C, Govindan R, Melnyk A, Fisher W
13. Richards D, Bruetman D, Anderson T, Chowhan N, Nattam S, Mantravadi P, Johnson C, Breen T, White A, Einhorn L (2008) Phase III study of cisplatin, etoposide, and concurrent chest radiation with or without consolidation docetaxel in patients with inoperable stage III non-small-cell lung cancer: the Hoosier Oncology Group and US Oncology. J Clin Oncol 26:5755-5760
14. Ho SB, Niehans GA, Lyftogt C, Yan PS, Cherwitz DL, Gum ET, Dahiya R, Kim YS (1993) Heterogeneity of mucin gene expression in normal and neoplastic tissues. Cancer Res 53:641-651 (Pubitemid 23059449)
15. MacLean GD, Miles DW, Rubens RD, Reddish MA, Longenecker BM (1996) Enhancing the effect of THERATOPE STn-KLH cancer vaccine in patients with metastatic breast cancer by pretreatment with low-dose intravenous cyclophosphamide. J Immunother Emphasis Tumor Immunol 19:309-316 (Pubitemid 26313521)
16. National Comprehensive Cancer Network (2010) NCCN clinical practice guidelines in oncology: non-small cell lung cancer. Available at: http://www.nccn.org. Accessed Feb. 2011
17. North S, Butts C (2005) Vaccination with BLP25 liposome vaccine to treat non-small cell lung and prostate cancers. Expert Rev Vaccines 4:249-257 (Pubitemid 40978689)
18. Palmer M, Parker J, Modi S, Butts C, Smylie M, Meikle A, Kehoe M, MacLean G, Longenecker M (2001) Phase I study of the BLP25 (MUC1 peptide) liposomal vaccine for active specific immunotherapy in stage IIIB/IV non-small-cell lung cancer. Clin Lung Cancer 3:49-57 (Pubitemid 32904315)
19. Parkin DM, Bray F, Ferlay J, Pisani P (2005) Global cancer statistics, 2002. CA Cancer J Clin 55:74-108 (Pubitemid 40372904)
20. Pilla L, Rivoltini L, Patuzzo R, Marrari A, Valdagni R, Parmiani G (2009) Multipeptide vaccination in cancer patients. Expert Opin Biol Ther 9:1043-1055
21. Roses RE, Xu M, Koski GK, Czerniecki BJ (2008) Radiation therapy and toll-like receptor signaling: implications for the treatment of cancer. Oncogene 27:200-207
22. Schiller JH, Harrington D, Belani CP, Langer C, Sandler A, Krook J, Zhu J, Johnson DH (2002) Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer. N Engl J Med 346:92-98 (Pubitemid 34438899)
23. Shepherd FA, Dancey J, Ramlau R, Mattson K, Gralla R, O'Rourke M, Levitan N, Gressot L, Vincent M, Burkes R, Coughlin S, Kim Y, Berille J (2000) Prospective randomized trial of docetaxel versus best supportive care in patients with non-small-cell lung cancer previously treated with platinum-based chemotherapy. J Clin Oncol 18:2095-2103 (Pubitemid 30324363)
24. Zotter S, Hageman PC, Lossnitzer A, Mooi WJ, Hilgers J (1988) Tissue and tumor distribution of human polymorphic epithelial mucin. Cancer Rev 11:55-101 (Pubitemid 19206475)